Condition (MeSH)
Failure to Thrive
ClinicalTrials.gov lists 83 trials for Failure to Thrive or a narrower condition beneath it. Ascendis Pharma Endocrinology Division A/S has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
83 of the 83 trials are tagged with Failure to Thrive itself; the rest are tagged with a narrower condition beneath it.
When did Failure to Thrive trials start? (23)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 3 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 6 |
| 2020 | 4 |
| 2019 | 6 |
| 2018 | 6 |
| 2017 | 2 |
| 2016 | 4 |
Showing 10 of 23 earlier years.
No forecast is made for this condition: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 54 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Failure to Thrive trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 11 |
| Phase 4 | 3 |
| Not applicable | 39 |
| Observational | 23 |
| Expanded access | 1 |
How many Failure to Thrive trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 6 |
| Recruiting | 3 |
| Active, not recruiting | 6 |
| Completed | 43 |
| Approved for marketing | 1 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Failure to Thrive trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Ascendis Pharma Endocrinology Division A/S | 4 |
| Ascendis Pharma A/S | 2 |
| AstraZeneca | 1 |
Which drugs are being tested for Failure to Thrive? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Increlex | 2 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| somatropin AQ | 5 |
| TransCon hGH | 2 |
| IFA Incomplete Freund's Adjuvant | 1 |
| Infant Formula | 1 |
| Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate | 1 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Failure to Thrive trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Severe morbidity or death | 107 | 1 |
| Spontaneous intestinal perforation | 9 | 1 |
| Necrotizing enterocolitis | 4 | 1 |
| COVID-19 | 3 | 1 |
| Arnold-Chiari malformation | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Failure to Thrive? (82)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Failure to Thrive, Metabolic Acidosis, and Diarrhea in a 7-Week-Old Infant. | Pediatrics | 2024 | Yes |
| Effect of lactoferrin in oral nutrition supplement (ONS) towards IL-6 and IL-10 in failure to thrive children with infection. | F1000Research | 2023 | Yes |
| Effects of cyproheptadine on body weight gain in children with nonorganic failure to thrive in Taiwan: A hospital-based retrospective study. | PloS one | 2021 | Yes |
| Impact of Steroid Therapy on Early Growth in Infants with Biliary Atresia: The Multicenter Steroids in Biliary Atresia Randomized Trial. | The Journal of pediatrics | 2018 | Yes |
| Environmental Enteric Dysfunction and Growth Failure/Stunting in Global Child Health. | Pediatrics | 2016 | Yes |
Showing 5 of 82 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.